Related Experiment Videos
Meningiomas, epidermal growth factor and progesterone
1Department of Medicine, Erasmus University Rotterdam, University Hospital Dijkzigt, The Netherlands.
Human Reproduction (Oxford, England)
|June 1, 1994
Summary
Progesterone may influence meningioma growth by increasing cell sensitivity to growth factors, not directly stimulating them. Antiprogestins like mifepristone may counteract these effects, offering potential treatment avenues for brain tumors.
Area of Science:
- Neuro-oncology
- Endocrinology
- Molecular Biology
Background:
- Meningiomas are common, typically benign brain tumors where regrowth after surgery is a clinical challenge.
- Progesterone receptors are present in many meningiomas, and increased growth during pregnancy suggests a hormonal link.
- Previous studies showed minimal direct effects of progesterone on cultured meningioma cells, despite receptor presence.
Purpose of the Study:
- To investigate the response of cultured human meningioma cells to epidermal growth factor (EGF).
- To determine how progesterone and mifepristone (RU486) modulate the EGF response in meningioma cells.
- To explore the potential of antiprogestins in managing meningioma growth.
Main Methods:
- Culturing human meningioma cells.
- Treating cells with EGF, progesterone, and mifepristone.
- Analyzing the mitogenic response and sensitivity to EGF.
Main Results:
- Progesterone in culture medium enhanced meningioma cell sensitivity to EGF-induced mitogenic stimuli.
- Progesterone itself did not exhibit direct mitogenic effects on the cells.
- Mifepristone effectively counteracted the stimulating effects of progesterone on cell sensitivity.
Conclusions:
- Progesterone appears to sensitize meningioma cells to growth factors rather than directly driving proliferation.
- Mifepristone's ability to block progesterone's effects suggests a therapeutic strategy for meningiomas.
- Further research into hormonal modulation of meningioma growth is warranted.